PURPOSE: To report the use of intracameral amphotericin B in the management of deep keratomycosis. METHODS: Four patients with deep keratomycosis unresponsive to conventional medical treatment underwent repeated intracameral injections of 5 microg amphotericin B in 0.1 mL 5% dextrose through a paracentesis. Three to 13 intracameral injections were given to each patient over 6 to 36 days. RESULTS: Three of the four patients had complete resolution of the ulcer. The fourth patient perforated and required evisceration. CONCLUSION: Preliminary experience suggests that intracameral injections of amphotericin B may have a role in the management of deep keratomycosis.
PURPOSE: To report the use of intracameral amphotericin B in the management of deep keratomycosis. METHODS: Four patients with deep keratomycosis unresponsive to conventional medical treatment underwent repeated intracameral injections of 5 microg amphotericin B in 0.1 mL 5% dextrose through a paracentesis. Three to 13 intracameral injections were given to each patient over 6 to 36 days. RESULTS: Three of the four patients had complete resolution of the ulcer. The fourth patient perforated and required evisceration. CONCLUSION: Preliminary experience suggests that intracameral injections of amphotericin B may have a role in the management of deep keratomycosis.
Authors: Sherif A Gaballa; Uday B Kompella; Omar Elgarhy; Ali M Alqahtani; Barbara Pierscionek; Raid G Alany; Hamdy Abdelkader Journal: Drug Deliv Transl Res Date: 2021-06 Impact factor: 4.617